Sarak, TanerSarıçam, ErsinRad, Abbas Yousefi2025-01-212025-01-2120202636-8579https://doi.org/10.32322/jhsm.654901https://search.trdizin.gov.tr/tr/yayin/detay/485503https://hdl.handle.net/20.500.12587/22561Aim: The interaction between cigarette smoking and efficacy of platelet function testing is not definitely shown. We aimed to investigate the effects of smoking on platelet reactivity by P2Y12 platelet function testing on the patients treated with clopidogrel. Material and Method: This prospective study contained 200 patients who underwent a previous stent implantation. Diagnostic coronary angiography was performed those patients due to chest pain. The clopidogrel resistance test was applied. Furthermore, the smoking effect on platelet reactivity was investigated. Then stent restenosis rates were investigated. Results: We found that 17% of the patients (34/200) clopidogrelresistant by P2Y12 platelet function test. We didn’t find any relationship between angiographic stent restenosis and clopidogrel resistance (p>0.05). There was statistically significant relationship between smoking and clopidogrel resistance. The smokers had also higher platelet reactivity level (>208 PRUs) as revealed by VerifyNow P2Y12 assay. Discussion: The test results achieved through the clopidogrel resistance by P2Y12 platelet function testing did not meet expectation with the angiographically observations. Conclusion: P2Y12 platelet function testing can be unclear in smoker patients.eninfo:eu-repo/semantics/openAccessGenel ve Dahili TıpArticle31424610.32322/jhsm.654901485503